Outlook Therapeutics, Inc.
OTLK
$0.64
$0.000.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -93.17% | 110.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -93.17% | 110.55% | |||
| Cost of Revenue | -88.61% | 404.39% | |||
| Gross Profit | 62.10% | 98.23% | |||
| SG&A Expenses | -20.56% | 10.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.57% | 15.30% | |||
| Operating Income | 22.93% | -4.03% | |||
| Income Before Tax | -356.30% | 80.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -356.30% | 80.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -356.30% | 80.69% | |||
| EBIT | 22.93% | -4.03% | |||
| EBITDA | 22.86% | -4.03% | |||
| EPS Basic | -173.16% | 85.80% | |||
| Normalized Basic EPS | -48.19% | 67.41% | |||
| EPS Diluted | -173.16% | 85.80% | |||
| Normalized Diluted EPS | -48.19% | 67.41% | |||
| Average Basic Shares Outstanding | 67.09% | 35.93% | |||
| Average Diluted Shares Outstanding | 67.09% | 35.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||